Loading…
Loading…
how different do you expect that to be in 5 years' time? How much of that might be down to the product mix
whether you have enough inventory in the US to support products like Rinvoq, Botox, Vraylar or Humira for the rest of this year
can you describe how you might think about the role of this product in the market? Is it only post maritide weight loss? Or how should we be thinking about that switching opportunity
Can you explain kind of why you think this is a better paradigm to be using? Or how you expect kind of physicians to select that right dose for the patient
Can you just talk a little bit about kind of how you anticipate this market evolving as we think about the oral PCSK9s and Merck's CORALreef lipids trial
Can you just help us understand kind of what is driving that primary change at that moment time relative to this new baseline on pricing
it would be great if you can kind of perhaps characterize those relative to what you're able to achieve through the year in 2025
What learnings are you taking from your first round in the PD-1 battle, the development and commercial kind of competition with Merck
a bit more context on kind of why this felt like it was the right time to announce this deal
Bristol's perspective there in terms of committed capital expenditure going forward
how you're approaching making those M&A decisions in the context of kind of internal success rates
how you're expecting that to flow
Can you just talk a little bit about TA alignment, kind of what good looks like
should we be thinking about the $800 million as a floor or as kind of a guide for 2026
I want to, I guess, zoom out a little bit to the White House deals and drug pricing, but particularly in the context of your HIV portfolio and higher Medicaid exposure
Why didn't you raise the launch expectations or the guidance as you thought about kind of the Yeztugo launch for the remainder of this year
whether there is any potential for an expedited PK or PD package relative to an efficacy trial or what might be needed
how you think kind of TROP2, DLL3, B7-H3 and all the other kind of targets that are being chased after in this space
how does this compare to kind of a traditional primary care launch -- what things are you accelerating
Can you just help us understand if you're anticipating any kind of accelerated pathways that you might be able to access in these ex-US countries that would enable launch in 2026 for orforglipron
Can you help us understand kind of the potential for expansion to the market with orfo? And should we expect to see a slowdown in getting new starts during the initial period of that orfo launch
we do see that kind of nausea, vomiting, constipation all appear a bit higher in this ACHIEVE-1 study. Can you talk a little bit about the differences
how many current patients on Zepbound are being covered by CVS Caremark today?
Can you just talk a little bit more about kind of the potential positioning, particularly in the context of kind of that single injectable GLP-1
How different do you expect that to be in 5 years' time? And how much of that could be attributed to product mix
how you're planning on reallocating in the context of KEYTRUDA SG&A relative to the newer opportunities
whether there's any risk of write-off as we think about the inventory that's sitting in the channel at Zhifei
can you help us kind of understand the parameter here
Can you just remind us or share with us what percentage of patients
are there more cuts that you can make going forward to that R&D plan? Or would that require actually stopping of programs
Could you imagine a world where patients might get kind of an INT twice in the course of their disease state if they were to progress
Could you imagine a world where patients might get kind of an INT twice in the course of their disease state if they were to progress
I just wanted to probe a little bit more on [ sigtolimod vedotin ] and positioning in that frontline setting, all comers relative to the Symbiotic-Lung-01 study
How do we think about 2027 as these studies start to annualize? And then kind of combining that with the element you just raised, Albert, of the AI investment
what factors supported Pfizer in garnering that unprecedented early termination of the waiting period from the U.S. Federal Trade Commission
Can you talk about kind of whether they still rank near the top or how you're seeing kind of opportunities out there
where you are kind of reallocating and investing versus where you're able to pull back
if you can provide any comments on inventory and kind of work that you're doing already to bring inventory into the US?
can you talk about whether these are similar or different to how oncology was set up earlier this year -- earlier last year?